» Articles » PMID: 28920295

Selective Nodal Irradiation of Regionally Advanced Non-small-cell Lung Cancer with Proton Therapy and IMRT: A Dosimetric Comparison

Overview
Journal Thorac Cancer
Date 2017 Sep 19
PMID 28920295
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives:   Evaluate the dosimetric impact of selective/elective nodal treatment with dose-escalated radiotherapy for regionally advanced non-small-cell lung cancer (NSCLC) using proton therapy (PT) or intensity-modulated radiotherapy (IMRT).

Methods:   Five consecutive patients with regionally advanced NSCLC underwent treatment planning for high-dose involved-field (IF) treatment (positron emission tomography-positive gross disease) with or without selective/elective nodal irradiation, defined as the extended field (EF). Four treatment plans were developed for each patient: i) IMRT to treat IF to 74 Gy (IFrT); ii) IMRT to treat high-risk nodes to 44 Gy and IF to 74 Gy (EFrT); iii) PT to treat IF to 74CGE (IFpT); and iv) PT to treat high-risk nodes to 44CGE and IF to 74CGE (EFpT). High-risk nodes were defined as mediastinal, hilar, and supraclavicular lymph node stations adjacent to foci of PET-positive gross disease. The IMRT and PT plans were isoeffective. Dose to organs at risk (OARs), including the lung, esophagus, heart and spinal cord, were evaluated.

Results:   The average IF clinical target volume (CTV) was 397 cc (344-428), while the average EF CTV was 642 cc (530-753 cc). Comparing IMRT with PT, mean lung dose reduced 3.4 Gy/CGE and 3.7 Gy/CGE; lung V20 reduced 4% and 5% for EF and IF, respectively.

Conclusions:   Selective/elective nodal irradiation with protons reduces normal-lung exposure compared to selective/elective nodal irradiation with IMRT.

Citing Articles

Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.

Kesarwala A, Ko C, Ning H, Xanthopoulos E, Haglund K, OMeara W Clin Lung Cancer. 2015; 16(3):237-44.

PMID: 25604729 PMC: 4410064. DOI: 10.1016/j.cllc.2014.12.001.


Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis.

Yin L, Yu X, Ren Y, Gu G, Ding T, Lu Z Multidiscip Respir Med. 2013; 8(1):21.

PMID: 23506629 PMC: 3608960. DOI: 10.1186/2049-6958-8-21.